Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Case of Reed's Syndrome: An Underdiagnosed Tumor Disorder.
Kontochristopoulos G, Kouris A, Balamoti E, Vavouli C, Markantoni V, Christofidou E, Antoniou C. Kontochristopoulos G, et al. Among authors: vavouli c. Case Rep Dermatol. 2014 Jul 25;6(2):189-93. doi: 10.1159/000365862. eCollection 2014 May. Case Rep Dermatol. 2014. PMID: 25232316 Free PMC article.
Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E, Vavouli C, Politou M, Befon A, Kostakis P, Rigopoulos D, Nicolaidou E. Rompoti N, et al. Among authors: vavouli c. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240-1247. doi: 10.1111/jdv.16202. Epub 2020 Feb 28. J Eur Acad Dermatol Venereol. 2020. PMID: 31953892
New-onset vitiligo after COVID-19 mRNA vaccination: A causal association?
Nicolaidou E, Vavouli C, Koumprentziotis IA, Gerochristou M, Stratigos A. Nicolaidou E, et al. Among authors: vavouli c. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e11-e12. doi: 10.1111/jdv.18513. Epub 2022 Aug 22. J Eur Acad Dermatol Venereol. 2023. PMID: 35971993 Free PMC article. No abstract available.
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Rompoti N, Stefanaki I, Panagakis P, Papoutsaki M, Politou M, Vavouli C, Befon A, Kousta F, Lazou E, Zaimi M, Koumprentziotis IA, Chasapi V, Rigopoulos D, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: vavouli c. J Eur Acad Dermatol Venereol. 2024 Mar 20. doi: 10.1111/jdv.19956. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38506605 No abstract available.
Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
Rompoti N, Politou M, Stefanaki I, Vavouli C, Papoutsaki M, Neofotistou A, Rigopoulos D, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: vavouli c. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):689-697. doi: 10.1111/jdv.18825. Epub 2023 Jan 4. J Eur Acad Dermatol Venereol. 2023. PMID: 36562663